Glaucoma is the leading cause of irreversible blindness worldwide, expected to affect 80 million by 2030.
The biggest known risk factors are ageing and higher pressure in the eye, with all currently licenced treatments working by lowering this pressure. But not everyone responds to treatment, and not everyone’s glaucoma progresses at the same rate. Why is this?
Findings from Moorfields Eye Hospital and UCL are bringing us closer to the answer, identifying new indicators that can show us who is likely to still have vision loss despite treatment. This study was conducted building on previous work funded by Fight for Sight.
The findings are likely to have an impact on how we monitor – and potentially treat – patients with glaucoma in the future. But first let’s break down the research.
Please read more here